This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Achillion CEO Needs to Deliver on Deal Talk

BOSTON ( TheStreet) -- It's a well-worn page in the investor conference presentation script: Biotech CEO takes stage and tells assembled audience of investors that his drugs have the makings to be best in class and that potential Big Pharma partners are all very interested in a deal.

This is pretty much what investors heard from Achillion Pharmaceuticals (ACHN - Get Report) CEO Michael Kishbauch Wednesday during his twirl through the Stifel Nicolaus Healthcare Conference.

Achillion expects to release proof-of-concept data from studies of three different experimental hepatitis C drugs before the end of the year, said Kishbauch. Among the expected results are 12-week, early virologic response data from a mid-stage study of Achillion's experimental protease inhibitor ACH-1625 combined with interferon and ribavirin.

Interest from Big Pharma in licensing or acquiring Achillion's Hep C drugs has increased since a spring Hep C research meeting in Europe, Kishbauch claims.

"Our talks have become intense," he said.

Talk is cheap, of course. Kishbauch leaves out the part in which Achillion is just one of many smaller Hep C drug developers desperate to find a big-moneyed partner. Anadys Pharmaceuticals (ANDS), Idenix Pharmaceuticals (IDIX) and Inhibitex (INHX), to name a few, are all saying singing the same tune.

This is not to say that deals won't get done or that Kishbauch is lying, it's just that for all the endless chatter and optimism about buyouts or lucrative partnerships amongst Hep C drug developers, actual deal activity has been rather anemic.

It's much easier to talk about deals than getting them done, apparently.

And it's not like Achillion hasn't gone down this road before. Achillion licensed a promising Hep C drug to Gilead Sciences (GILD - Get Report) but that drug blew up in 2007 due to safety problems and was discontinued.

The Hep C treatment market is changing fast. The launch this spring of Vertex Pharmaceuticals' (VRTX - Get Report) Incivek and Merck's (MRK) Victrelis dramatically improved the outlook for patients, but better drugs, better combinations of drugs, are on the way. Achillion is late to the game but hopes to play catch up by developing drugs that can be combined together to create more effective, all oral treatment options. (That means getting rid of weekly shots of interferon.)
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACHN $8.65 -1.70%
GILD $88.79 -8.50%
IDIX $24.50 0.20%
VRTX $84.79 -2.30%
AAPL $93.39 -1.50%


Chart of I:DJI
DOW 17,703.69 -127.07 -0.71%
S&P 500 2,060.38 -15.43 -0.74%
NASDAQ 4,772.0860 -33.2050 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs